Schiller L R, Hogan R B, Morawski S G, Santa Ana C A, Bern M J, Norgaard R P, Bo-Linn G W, Fordtran J S
Gastroenterology. 1987 Jan;92(1):151-60. doi: 10.1016/0016-5085(87)90852-3.
We studied radiolabeled fecal bile acid excretion in 11 normal subjects and 17 patients with idiopathic chronic diarrhea for three major purposes: to establish normal values for this test in the presence of increased stool volumes (induced in normal subjects by ingestion of poorly absorbable solutions); to test for bile acid malabsorption in the patients and to correlate this with an independent test of ileal function, the Schilling test; and to compare the results of the bile acid excretion test with the subsequent effect of a bile acid binding agent (cholestyramine) on stool weight. In normal subjects fecal excretion of the radiolabel was increased with increasing stool volumes. As a group, patients with idiopathic chronic diarrhea excreted radiolabeled bile acid more rapidly than normal subjects with induced diarrhea (t1/2 56 +/- 8 vs. 236 +/- 60 h, respectively, p less than 0.005). There was a statistically significant positive correlation between t1/2 of radiolabeled bile acid and Schilling test results in these patients. Although 14 of 17 patients absorbed labeled taurocholic acid less well than any of the normal subjects with comparable volumes of induced diarrhea, cholestyramine had no statistically significant effect on stool weight in the patient group, and in none of the patients was stool weight reduced to within the normal range. In summary, most patients with idiopathic chronic diarrhea have bile acid malabsorption (as measured by fecal excretion of labeled bile acid), but they do not respond to cholestyramine therapy with a significant reduction in stool weight. Although the significance of these findings was not clearly established, the most likely interpretation is that bile acid malabsorption is a manifestation of an underlying intestinal motility or absorptive defect rather than the primary cause of diarrhea.
我们对11名正常受试者和17名特发性慢性腹泻患者的放射性标记粪便胆汁酸排泄情况进行了研究,主要有三个目的:在粪便量增加的情况下(通过让正常受试者摄入难吸收溶液来诱导)确定该检测的正常值;检测患者是否存在胆汁酸吸收不良,并将其与回肠功能的独立检测——希林试验进行关联;比较胆汁酸排泄试验的结果与胆汁酸结合剂(消胆胺)对粪便重量的后续影响。在正常受试者中,放射性标记物的粪便排泄量随粪便量增加而增加。作为一个群体,特发性慢性腹泻患者排泄放射性标记胆汁酸的速度比诱导腹泻的正常受试者更快(半衰期分别为56±8小时和236±60小时,p<0.005)。在这些患者中,放射性标记胆汁酸的半衰期与希林试验结果之间存在统计学上显著的正相关。虽然17名患者中有14名吸收标记牛磺胆酸的情况比任何具有可比诱导腹泻量的正常受试者都差,但消胆胺对患者组的粪便重量没有统计学上显著的影响,而且没有一名患者的粪便重量降至正常范围内。总之,大多数特发性慢性腹泻患者存在胆汁酸吸收不良(通过标记胆汁酸的粪便排泄来衡量),但他们对消胆胺治疗没有出现粪便重量显著减轻的情况。虽然这些发现的意义尚未明确确定,但最可能的解释是胆汁酸吸收不良是潜在肠道动力或吸收缺陷的一种表现,而不是腹泻的主要原因。